Compounded vs. FDA-Approved GLP-1s: What the FDA Actually Says in 2026

Almost every cheap GLP-1 subscription advertised online today is a compounded medication. Almost every buyer we have watched go through this process assumes "compounded" means something like "generic". It does not, and the gap between those two ideas is where people get hurt financially and occasionally medically. Here is the distinction, sourced from the FDA's own consumer guidance.

1. Compounded is not generic, and it is not FDA-approved

A generic drug has been reviewed by the FDA and shown to be equivalent to the brand product. A compounded drug has not been reviewed at all. The FDA states directly that compounded drugs are not FDA approved, which means the agency does not evaluate them for safety, effectiveness or quality before they reach patients.

The providers themselves generally say this, in small type. TrimRx's terms state its compounded product is neither FDA-approved nor a generic. WellMedr carries the required notice that compounded GLP-1s have not been evaluated by the FDA. They are not hiding it. They are just not leading with it.

2. The FDA's position on when compounding is appropriate is narrower than the marketing suggests

The agency's stated recommendation is that compounded drugs should be used in patients whose medical needs cannot be met by an FDA-approved drug. That is a clinical threshold, not a pricing one. "The approved version costs too much" is a completely understandable reason to buy compounded medication, and it is the actual reason most people do — but it is not the reason the regulatory pathway exists. Knowing that changes how you should read a $59 offer.

3. Some ingredients being marketed cannot legally be compounded at all

This is the sharpest line in the FDA's guidance and the one we would most want a reader to remember. Retatrutide and cagrilintide cannot be used in compounding under federal law. They are not components of any FDA-approved drug and have not been found safe and effective for any condition. The FDA says it has warned telehealth companies for marketing unapproved drugs including retatrutide, warned ingredient distributors for selling it to compounders, and warned outsourcing facilities for repackaging it.

If a telehealth brand offers you retatrutide, you are not getting an early look at the next generation of weight-loss medicine. You are buying something outside the legal compounding framework. Walk away.

4. Salt forms of semaglutide are a red flag

The FDA notes that some compounded products use salt forms — semaglutide sodium or semaglutide acetate — which are different active ingredients from the one in the approved drugs. The agency says it is not aware of any lawful basis for using them in compounding. If a provider will not tell you plainly which form of the active ingredient it dispenses, that is information in itself.

5. Dosing errors are a documented, repeated harm

The FDA reports receiving multiple adverse event reports, some involving hospitalisation, that may relate to dosing errors with compounded injectable semaglutide — patients measuring and self-administering the wrong amount, and in some cases clinicians miscalculating doses. It also reports adverse events that may relate to patients being prescribed doses beyond what appears on the approved label, whether by larger single doses, more frequent doses, or faster titration.

This is a structural risk of the compounded model, not bad luck. Branded pens come in fixed, labelled doses. Compounded vials often require you to draw a volume yourself. If you are choosing compounded medication, ask the provider exactly how the dose is measured and get written instructions.

6. Cold chain: if it arrives warm, do not use it

Injectable GLP-1s require refrigeration. The FDA says it has received complaints that some compounded GLP-1 shipments arrived warm or with inadequate ice packs, and its recommendation is blunt: do not use an injectable GLP-1 that arrives warm or insufficiently refrigerated. This is one reason we treat overnight or expedited shipping as a real feature rather than a marketing garnish when we compare providers.

7. Fraudulent and counterfeit product is circulating

The FDA says it is aware of fraudulent compounded semaglutide and tirzepatide sold in the US carrying false label information — in some cases naming compounding pharmacies that do not exist, in others naming real pharmacies that did not make the product. It is also aware of counterfeit Ozempic in the US market. Separately, the agency has established an import alert covering GLP-1 active pharmaceutical ingredients with potential quality concerns.

8. The adverse event numbers, and why they understate things

As of May 31, 2026, the FDA reported having received 990 adverse event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. The agency also points out that state-licensed pharmacies that are not outsourcing facilities are not required by federal law to report adverse events, so the true count is likely higher. It also notes that many reported events look similar to those seen with the approved versions.

We are not presenting these numbers as proof that compounded GLP-1s are dangerous. Reporting counts are not rates, and there is no denominator here. We are presenting them because they exist, they are official, and nobody selling you a subscription is going to mention them.

9. Approved-drug names on a compounded menu

This is the pattern we now check for first, because we keep finding it. A provider’s homepage advertises the approved medications by name — Wegovy, Zepbound, and newer arrivals — and then the actual catalogue sells compounded product. SkinnyRx is a live example: its homepage promotes "FDA-approved Wegovy, Foundayo and other GLP-1s," but on the product pages both Wegovy Pill and Foundayo are marked Unavailable, with no price attached. The only things you can actually buy are compounded semaglutide and compounded tirzepatide. We wrote that up in our SkinnyRx review.

This is not necessarily deceptive on purpose — supply of the branded products moves, and a site can lag. But the effect on a shopper is the same either way: you arrive believing you are buying an FDA-approved drug and you leave with a compounded one, which is a materially different product with a materially different regulatory status. Everything in the eight points above applies to what you actually receive, not to what was advertised on the way in.

The counter-example is worth naming too. Embody places the FDA compounding disclaimer directly underneath the price on the page where you choose a plan, rather than burying it in a footer. You can disagree with the business model and still recognise that as the right place to put the disclosure. Detail in our Embody review.

What to do: before you pay, open the product page for the specific medication you think you are buying and confirm three things — that it has a price, that it is in stock, and that the page says either "FDA-approved" or "compounded." If the site will not tell you which one you are getting, that is your answer.

The FDA's own telehealth warning signs, in plain language

The agency publishes a list of red flags for buying medication through telehealth companies. Paraphrased, be wary if a company:

• tells you its compounded drug is the same as the FDA-approved drug;
• offers prices that are implausibly low;
• sends medication that looks different from what you have received before, or arrives damaged or without usage instructions;
• does not require screening and a prescription from a licensed clinician;
• has no licensed clinician available to answer questions after the medication arrives;
• has spelling errors on the label or lists an incorrect pharmacy address;
• names a pharmacy on the label that you cannot verify exists.

That last one is checkable in about two minutes. Every state has a searchable pharmacy licence lookup. Do it before your second refill, not after a problem.

What we do with this when we review providers

We do not treat "compounded" as disqualifying, because for many people the approved product is genuinely unaffordable and the compounded route is the only route. We do treat three things as non-negotiable in a provider: it names the active ingredient form clearly, it ships cold-chain properly, and it gives you a real clinician you can reach after the box arrives. Read our review method and our provider comparison.

Source